Skip to content

Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis

A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02549001
Enrollment
953
Registered
2015-09-14
Start date
2015-08-20
Completion date
2018-09-17
Last updated
2018-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Onychomycosis

Keywords

Onychomycosis, Nail fungus

Brief summary

The purpose of this study is to determine whether P-3058 nail solution is a safe and effective treatment for onychomycosis.

Interventions

DRUGamorolfine 5%
DRUGP-3058 10%
DRUGvehicle of P-3058 10%

Sponsors

Polichem S.A.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Patients aged 12 years and older of any race. * Males or females. * Patients with onychomycosis involving ≥ 20% to ≤ 50% of target big toenail. * Patients with a positive KOH examination and culture positive for dermatophyte

Exclusion criteria

* Presence of yellow spikes on the target nail. * Presence of dermatophytoma on the target nail. * Presence of nail thickness exceeding 2 mm. * Patients with proximal subungual involvement * Patients with severe plantar or moccasin tinea pedis * Patients with nail abnormalities due to other conditions * Patients with life expectancy less than 2 years. * Chemotherapy, immunosuppressive therapy in the 12 weeks prior to Screening visit (V1). * Systemic corticosteroids, antimetabolites and immune-stimulants therapy in the 4 weeks prior to Screening visit (V1). * HIV infection or any other immunodeficiency. * Alcohol or substance abuse. * Patients with history of allergic reactions to terbinafine or its excipients. * Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period.

Design outcomes

Primary

MeasureTime frame
Complete cure of target great toenail defined as negative KOH microscopy, negative culture for dermatophytes and target nail totally clear.Week 60

Secondary

MeasureTime frame
Responder rate of the target toenail, defined as negative KOH microscopy, negative culture for dermatophytes and ≤10% residual involvement of the target toenail.Week 60
Negative culture rate for dermatophytes of the target nail.Week 60
Mycological cure defined as negative KOH microscopy and negative culture for dermatophytes of the target nail.Week 60
Overall safety by recording any AE during the entire study duration and the local tolerability by means of severity scores for skin irritation.Week 60

Countries

Belgium, Bulgaria, Czechia, Germany, Greece, Hungary, Iceland, Latvia, Lithuania, Poland, Russia, Slovakia, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026